Therapy with the CB2 agonist was established to limit albuminuria in obese animal models [139] and in a mouse model of diabetic nephropathy [91], which opened new perspectives to the treatment of patients with diabetes. The gene discussed is CNR2; the disease is diabetes mellitus.